The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

NCT04619680 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

103

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Fibrosis
Interstitial Lung Disease
Respiratory Disease

Interventions

DRUG: Nintedanib
DRUG: Placebo

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

Boehringer Ingelheim